<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ETF Trends &#187; XBI</title>
	<atom:link href="http://www.etftrends.com/tag/xbi/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.etftrends.com</link>
	<description>Setting the Pace for Exchange Traded Funds</description>
	<lastBuildDate>Sun, 12 Feb 2012 11:00:32 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Biotech ETFs Break Out</title>
		<link>http://www.etftrends.com/2012/01/biotech-etfs-break-out/</link>
		<comments>http://www.etftrends.com/2012/01/biotech-etfs-break-out/#comments</comments>
		<pubDate>Thu, 19 Jan 2012 14:45:51 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[Feature Stories]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=74303</guid>
		<description><![CDATA[The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector&#8217;s largest ETF posting a gain of 20% over the past three months.
The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up 9.6% year to date, compared with a 4.1% [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2012/01/biotech-etfs-break-out/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Teva, Cephalon Boost Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/#comments</comments>
		<pubDate>Mon, 02 May 2011 15:45:58 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52575</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) rallied to open the week after Teva Pharmaceutical (NasdaqGS: TEVA) said it’s buying Cephalon (NasdaqGS: CEPH) for $6.8 billion in a blockbuster sector deal.
The combined company would represent about $7 billion in annual sales. Shares of Teva and Cephalon were both up more than 3% in recent trading.
&#8220;This is transforming [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/05/teva-cephalon-boost-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>April ETF Performance Report</title>
		<link>http://www.etftrends.com/2011/04/april-etf-performance-report-3/</link>
		<comments>http://www.etftrends.com/2011/04/april-etf-performance-report-3/#comments</comments>
		<pubDate>Fri, 29 Apr 2011 22:08:14 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[ETF Performance Reports]]></category>
		<category><![CDATA[DBS]]></category>
		<category><![CDATA[EWG]]></category>
		<category><![CDATA[Silver]]></category>
		<category><![CDATA[SIVR]]></category>
		<category><![CDATA[SLV]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=52477</guid>
		<description><![CDATA[Markets were in full bloom in April, as corporate earnings helped push markets and exchange traded funds (ETFs) higher.  The Dow Jones Industrial Average gained nearly 4% this month and had its highest close since May 2008.  The S&#38;P 500 rose about 3% and the Nasdaq gained 3.5% for the month.
Silver ETFs were the top [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/april-etf-performance-report-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Earnings, Drug Data to Lift Biotech ETFs</title>
		<link>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Apr 2011 12:55:22 +0000</pubDate>
		<dc:creator>John Spence</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=51598</guid>
		<description><![CDATA[Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug.
The data on the drug, BG-12, was “very competitive versus other approved and pipeline MS therapies” and the results are “a significant catalyst for Biogen shares,” said [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/04/biogen-earnings-drug-data-to-lift-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs And A Global Approach Help Investors Access Biotech</title>
		<link>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/</link>
		<comments>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/#comments</comments>
		<pubDate>Fri, 11 Mar 2011 09:00:37 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=47499</guid>
		<description><![CDATA[Investing in biotech stocks and companies is so much like gambling, the risk is sometimes not worth it. Why not mitigate the risk and invest in an exchange traded fund (ETF) instead, which will give investors exposure to several companies at once.[Dissipate The Risk In Biotechnology With ETFs.]
According to MinyanVille, the process of New Drug [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/03/etfs-and-a-global-approach-help-investors-access-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Biotechnology ETFs to Play Innovation</title>
		<link>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/</link>
		<comments>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 22:00:10 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[HOLDRs]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46796</guid>
		<description><![CDATA[While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector.
Currently, the biotech industry is full of fast-growing and very profitable companies; however, [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/5-biotechnology-etfs-play-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ETFs Turn Sunny Side Up on M&amp;A and Earnings</title>
		<link>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/</link>
		<comments>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 16:30:59 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[Industrial Metals]]></category>
		<category><![CDATA[NASDAQ]]></category>
		<category><![CDATA[PMR]]></category>
		<category><![CDATA[QTEC]]></category>
		<category><![CDATA[Real Estate]]></category>
		<category><![CDATA[Retail]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[VPU]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=46623</guid>
		<description><![CDATA[Reversing a few days of weak starts, exchange traded funds (ETFs) opened higher as investors respond to another round of earnings, corporate deal making and economic reports.

U.S. core producer prices in January rose to their highest rate in more than two years, hinting at a build-up in inflation pressures as the recovery gathers pace, a [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/02/etfs-turn-sunny-side-ma-earnings/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sector ETFs to Play the State of the Union Address</title>
		<link>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/</link>
		<comments>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/#comments</comments>
		<pubDate>Wed, 26 Jan 2011 20:00:06 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Socially Responsible ETFs]]></category>
		<category><![CDATA[Aerospace & Defense]]></category>
		<category><![CDATA[Alternative Energy]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clean Energy]]></category>
		<category><![CDATA[Energy]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[FXH]]></category>
		<category><![CDATA[GEX]]></category>
		<category><![CDATA[Green ETFs]]></category>
		<category><![CDATA[GRID]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[Infrastructure]]></category>
		<category><![CDATA[ITA]]></category>
		<category><![CDATA[IYW]]></category>
		<category><![CDATA[NASI]]></category>
		<category><![CDATA[PBW]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PPA]]></category>
		<category><![CDATA[QQEW]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLK]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=45357</guid>
		<description><![CDATA[In his State of the Union address Tuesday, President Barack Obama touched upon the major problems that have crippled our nation and offered an essential directive to invest in our future. If Obama&#8217;s proposals become actualities, something that&#8217;s not necessarily a certainty, then the exchange traded funds (ETFs) below could make moves.
President Obama stressed the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/sector-etfs-play-state-union-address/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dissipate the Risk In Biotechnology With ETFs</title>
		<link>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/</link>
		<comments>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/#comments</comments>
		<pubDate>Tue, 18 Jan 2011 22:00:17 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[BIS]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=44690</guid>
		<description><![CDATA[The biotechnology sector offers investors the opportunity to bet big and win big, but the potential downside can make a huge dent in your wallet. Perhaps a biotech exchange traded fund (ETF) is more to your liking?
The largest and most liquid broad-based biotech sector iShares Nasdaq Biotechnology (NASDAQ: IBB), which reflects the performance of the [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2011/01/dissipate-risk-biotechnology-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Play the Booming Biotech Sector With ETFs</title>
		<link>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/</link>
		<comments>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 23:00:29 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BBH]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43168</guid>
		<description><![CDATA[Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year.
In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345 involved in the development, manufacture or sales of therapeutic products, according to PharmaLive. The biotech sector also [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/play-booming-biotech-sector-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deal-Making Drives ETFs Higher</title>
		<link>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/</link>
		<comments>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/#comments</comments>
		<pubDate>Tue, 21 Dec 2010 16:30:43 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Global ETFs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Asia]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Emerging Markets]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[EWP]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IGV]]></category>
		<category><![CDATA[Spain]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XPP]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=43404</guid>
		<description><![CDATA[Exchange traded funds (ETFs) are moving up on Tuesday, lifted by premarket gains for Adobe Systems Inc. after upbeat earnings as well as deal news involving Martek Biosciences Corp. and Chrysler Financial.

Shares of Adobe (NYSE: ADBE) are flying high up over 6% today after the firm posted late Monday fiscal fourth-quarter results that beat Wall [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/12/deal-making-drives-etfs-higher/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Health Care ETFs May Be In the Clear</title>
		<link>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/</link>
		<comments>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/#comments</comments>
		<pubDate>Wed, 10 Nov 2010 19:00:49 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[IHF]]></category>
		<category><![CDATA[IXJ]]></category>
		<category><![CDATA[IYH]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PJP]]></category>
		<category><![CDATA[PTH]]></category>
		<category><![CDATA[RXD]]></category>
		<category><![CDATA[RXL]]></category>
		<category><![CDATA[RYH]]></category>
		<category><![CDATA[VHT]]></category>
		<category><![CDATA[XBI]]></category>
		<category><![CDATA[XLV]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40871</guid>
		<description><![CDATA[After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don&#8217;t believe there&#8217;s anything to worry about for a while.
First, with most corporations backing major Congressional players, it is almost certain that the medical industry [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/why-health-care-etfs-may-be-in-the-clear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs May Soon Face Challenges</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/#comments</comments>
		<pubDate>Sat, 06 Nov 2010 20:00:26 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40680</guid>
		<description><![CDATA[The Republican takeover of the House this week could have a negative impact on biotechnology exchange traded funds (ETFs).
Kenneth Chang for The New York Times reports that research and development at nonmilitary agencies — including those that sponsor science and health research — would fall 12.3 %, to $57.8 billion, down from President Obama’s requested [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-may-soon-face-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech ETFs Readying to Deliver the Goods</title>
		<link>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/</link>
		<comments>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/#comments</comments>
		<pubDate>Tue, 02 Nov 2010 20:00:53 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[Health Care]]></category>
		<category><![CDATA[Hot Story]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=40365</guid>
		<description><![CDATA[Biotechnology exchange traded funds (ETFs) could be poised to deliver the goods as an aging population and demand for new treatments stokes growth in the sector.
A slew of factors are driving the sector these days, explains PR.com. They include:

Increasing demand for biotechnology drugs with enhanced efficiency, safety and popularity.
Revision of regulations and standards in favor [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/11/biotech-etfs-readying-deliver-goods/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>5 Things That Drive Biotech ETFs</title>
		<link>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/</link>
		<comments>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/#comments</comments>
		<pubDate>Thu, 21 Oct 2010 22:00:55 +0000</pubDate>
		<dc:creator>Tom Lydon</dc:creator>
				<category><![CDATA[All]]></category>
		<category><![CDATA[Current Affairs]]></category>
		<category><![CDATA[Long-Short ETFs]]></category>
		<category><![CDATA[Sector ETFs]]></category>
		<category><![CDATA[BIB]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[FBT]]></category>
		<category><![CDATA[IBB]]></category>
		<category><![CDATA[PBE]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[XBI]]></category>

		<guid isPermaLink="false">http://www.etftrends.com/?p=39693</guid>
		<description><![CDATA[The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here&#8217;s what drives the sector and exchange traded funds (ETFs) that let you play it.
Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven by and dependent on several key things:

Mergers and acquisitions: [...]]]></description>
		<wfw:commentRss>http://www.etftrends.com/2010/10/5-things-drive-biotech-etfs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

